Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Predemtec GmbH receives seed financing from High-Tech Gruenderfonds
for developing a blood test to diagnose Alzheimer`s Disease

There are approximately 36 million patients worldwide suffering from dementia. With two thirds of all cases, Alzheimer's disease (AD) is the most frequent form of dementia.
Despite significant neuropsychological and technical efforts, the diagnosis of Alzheimer's disease is laborious and not very reliable. Furthermore, AD is still diagnosed much too late. Due to this delay possible preventive and therapeutic possibilities remain unused. To this day, no test suitable for routine application can detect the disease in a simple, reliable and cost-efficient way.
The results of previous clinical trials show that the absence of a reliable diagnostic method makes it difficult to develop new drugs for the treatment or cure of AD.
Predemtec GmbH from Hennigsdorf near Berlin develops a test which allows to diagnose Alzheimer's disease with a specificity and sensitivity of over 90% by means of immunological detection of 6 different blood biomarkers. 'With its patented combination of biomarkers, the test not only enables a reliable diagnosis of Alzheimer's, but also permits a differential diagnosis and thus the determination of vascular dementia, with 20% the second most common cause of dementia', says Dr. Patrick Scotton, CEO and co-founder of the start-up in Hennigsdorf near Berlin.
'It is generally agreed that Alzheimer's dementia starts 10 to 15 years before the first clinical symptoms appear. Compensation mechanisms of the central nervous system will counterbalance pathological processes for a long time, hence the disease can go unnoticed for a long period of time', adds Ms Dr. Annegret Feuerhelm-Heidl, founder and CSO/managing director. 'In an ongoing trial we also examine the possibilities of an early diagnosis of Alzheimer's disease. The first results of our test are available and they are very promising', continues Ms Dr. Feuerhelm-Heidl.
Dr. Martin Pfister, Senior Investment Manager at High-Tech Gruenderfonds adds: 'We were impressed by the rather advanced stage of the test and Predemtec's good cooperation with relevant clinics such as the Charité in Berlin. The fact that the test is initially aimed at a robust AD diagnosis as well as a clean differential diagnosis shows the professional approach of the team headed by Ms Feuerhelm-Heidl and Mr Scotton.'
About Predemtec GmbH: The company is headquartered in Hennigsdorf and was founded in September 2011. The biomarker set is prevalidated and patented. Clinical trials for the biomarkers' validation on secured Alzheimer patients and for the early diagnosis of MCI patients (mild cognitive impairment) are under way.
Contact: Predemtec GmbH - Dr. Patrick Scotton, Neuendorfstrasse 18a, 16761 Hennigsdorf,,

About High-Tech Gruenderfonds
High-Tech Gruenderfonds invests in young, high potential high-tech start-ups. The seed financing provided is designed to enable start-ups to take an idea through prototyping and to market launch. Typically, High-Tech Gruenderfonds invests EUR 500,000 in the seed stage, with the potential for up to a total of EUR 2 million per portfolio company in follow-on financing. Investors in this public/private partnership include the Federal Ministry of Economics and Energy, the KfW Banking Group, as well as strategic corporate investors including ALTANA, BASF, Bayer, B. Braun, Robert Bosch, CEWE, Daimler, Deutsche Post DHL, Deutsche Telekom, Evonik, Lanxess, media + more venture Beteiligungs GmbH & Co. KG, METRO, Qiagen, RWE Innogy, SAP, Tengelmann and Carl Zeiss. High-Tech Gruenderfonds has about EUR 576 million under management in two funds (EUR 272 million HTGF I, EUR 304 million HTGF II).
High-Tech Gruenderfonds Management GmbH
Dr. Martin Pfister
Schlegelstrasse 2
53113 Bonn
Phone: +49 (0)228 823001-00

Publisher Contact Information:


Company profile of Predemtec
Past press releases of Predemtec.


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
Feb 14€19.0MBiopharmaceuticals
Feb 14N/AInternet services
Feb 14€4.6MBusiness applications
Feb 13€13.0MBiopharmaceuticals
Feb 13€25.0MMedical devices
Feb 13€15.0MBusiness applications

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.